- Previous Close
3.4700 - Open
3.5400 - Bid 3.2800 x 300
- Ask 3.3300 x 600
- Day's Range
3.2800 - 3.5700 - 52 Week Range
1.4400 - 6.4200 - Volume
867,926 - Avg. Volume
2,141,780 - Market Cap (intraday)
218.865M - Beta (5Y Monthly) 1.93
- PE Ratio (TTM)
-- - EPS (TTM)
-0.9500 - Earnings Date Feb 26, 2025 - Mar 3, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.75
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
www.cardiffoncology.comRecent News: CRDF
View More
Performance Overview: CRDF
Trailing total returns as of 1/14/2025, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CRDF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CRDF
View MoreValuation Measures
Market Cap
230.84M
Enterprise Value
174.86M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
228.30
Price/Book (mrq)
4.67
Enterprise Value/Revenue
254.15
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-38.33%
Return on Equity (ttm)
-67.57%
Revenue (ttm)
688k
Net Income Avi to Common (ttm)
-43.01M
Diluted EPS (ttm)
-0.9500
Balance Sheet and Cash Flow
Total Cash (mrq)
57.67M
Total Debt/Equity (mrq)
3.41%
Levered Free Cash Flow (ttm)
-19.85M
Research Analysis: CRDF
View MoreCompany Insights: CRDF
CRDF does not have Company Insights
Research Reports: CRDF
View MoreDaily – Vickers Top Buyers & Sellers for 09/23/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 09/14/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Insider Picks for 06/18/2021
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 06/17/2021
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.